Germany
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-24 — Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany’s Persistent Underpayment for Innovative Pharmaceutical Products: USTR initiated a Section 301 investigation into Germany’s alleged persistent underpayment for innovative pharmaceutical products, with a public hearing and comment period announced. (novelty: 3)
Open questions
Related
Contributing findings
Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products
24-jun-2026
novelty 3
per-area 3
introduces